Meda expands collaboration with Cipla

Published: 6-Jun-2013
Research & Development Pharmaceutical

Expands its exclusive rights to allergic rhinitis treatment Dymista


Meda, a specialist Swedish pharmaceutical firm, is broadening its collaboration with Indian pharmaceutical company Cipla, thereby expanding its exclusive rights to Dymista and future product development.

Through the extended partnership, Meda will have full coverage in all growth markets in Latin America, South America, Middle East, Africa and Asia, including more than 120 new markets.

Meda and Cipla will cooperate on product development of allergic rhinitis treatment Dymista. Cipla will be responsible for formulation, with Meda handling clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista and any new products developed.

‘Through this expanded partnership, we secure opportunities for global commercialisation of Dymista and optimise future product development,’ said Anders Lönner, Meda’s CEO. ‘Not least, we see great potential in several priority growth markets such as China.’

Meda’s product portfolio is divided into three main areas of specialist products, over-the-counter medicines and branded generics.

  • Companies:
  • Cipla
  • Meda
See more

You may also like

Research & Development

Indian Cipla funnels $1 million into facility in Minsk

Read more
The facility will be used to localise the production of innovative solid medicines in Belarus

Trending Articles

  1. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  2. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  3. Lessons learned: AstraZeneca’s supply chain resilience during the pandemic With 26 manufacturing facilities and a global network of more than 250 suppliers, AstraZeneca’s Global Operations Manufacturing footprint is not only large in scale, it's also highly complex and positioned to deliver medicines to patients worldwide
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Indian Cipla funnels $1 million into facility in Minsk

The facility will be used to localise the production of innovative solid medicines in Belarus
Finance

Mylan to acquire Meda in US$9.9bn cash and stock deal

Will create a leading pharma firm with a portfolio of branded and generic medicines and a strong portfolio of over-the-counter products
Finance

Cipla to acquire two US generics companies for $550m

Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base
Manufacturing

Cipla signs distribution agreement with Serum Institute of India

Enters the market for paediatric vaccines in Europe
Finance

2014 Sunday Times Rich List sees entry of more pharma executives

Ernesto and Kirsty Bertarelli are still out ahead of the rest
Pharmaceutical

Cipla aims for export growth

Looking to increase its exports from current 55% to more than 70% of turnover
Ingredients

Indian API market on the up as domestic drug prices fall

Indian API manufacturers are branching out into new markets, while international suppliers could be hit by lower prices in the domestic market, writes Asia correspondent A Nair
Subscribe now